Long-term Study of TAK-875

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01433406
Recruitment Status : Completed
First Posted : September 14, 2011
Last Update Posted : January 27, 2014
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety and efficacy of long-term treatment with TAK-875 in diabetic patients.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Drug: TAK-875 Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1222 participants
Intervention Model: Parallel Assignment
Study Start Date : October 2011
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Arm Intervention/treatment
Experimental: TAK-875 25 mg
(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
Drug: TAK-875
Experimental: TAK-875 50 mg
(long-term monotherapy or long-term combination therapy with anti-diabetic drugs)
Drug: TAK-875

Primary Outcome Measures :
  1. Adverse events [ Time Frame: From Baseline to Week 53 ]
    Frequency, severity, and time to onset of adverse drug reactions tabulated by each symptom. Adverse events are defined as any unfavorable and unintended signs, symptoms or diseases temporally associated with the use of a medicinal product reported from the first dose of study drug to the last dose of study drug.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The participant is an outpatient.
  2. The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.

Exclusion Criteria:

  1. The participant has any serious cardiac disease, serious cerebrovascular disorder, or any serious pancreatic or hematological disease.
  2. The participant is considered ineligible for the study for any other reason by the investigator or sub-investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01433406

  Hide Study Locations
Nagoya-shi, Aichi, Japan
Chiba-shi, Chiba, Japan
Funabashi-shi, Chiba, Japan
Katori-shi, Chiba, Japan
Kisarazu-shi, Chiba, Japan
Matsudo-shi, Chiba, Japan
Matsuyama-shi, Ehime, Japan
Nihama-shi, Ehime, Japan
Saijo-shi, Ehime, Japan
Fukuoka-shi, Fukuoka, Japan
Kitakyushu-shi, Fukuoka, Japan
Onga-gun, Fukuoka, Japan
Annaka-shi, Gunma, Japan
Takasaki-shi, Gunma, Japan
Aki-gun, Hiroshima, Japan
Hiroshima-shi, Hiroshima, Japan
Chitose-shi, Hokkaido, Japan
Sapporo-shi, Hokkaido, Japan
Amagasaki-shi, Hyougo, Japan
Nishinomiya-shi, Hyougo, Japan
Mito-shi, Ibaragi, Japan
Naka-shi, Ibaragi, Japan
Tsuchiura-shi, Ibaragi, Japan
Ushiku-shi, Ibaragi, Japan
Sakade-shi, Kagawa, Japan
Izumi-shi, Kagoshima, Japan
Kamakura-shi, Kanagawa, Japan
Yamato-shi, Kanagawa, Japan
Kochi-shi, Kochi, Japan
Suzaki-shi, Kochi, Japan
Kumamoto-shi, Kumamoto, Japan
Minamata-shi, Kumamoto, Japan
Uji-shi, Kyoto, Japan
Miyazaki-shi, Miyazaki, Japan
Matsumoto-shi, Nagano, Japan
Nagasaki-shi, Nagasaki, Japan
Omura-shi, Nagasaki, Japan
Oita-shi, Oita, Japan
Okayama-shi, Okayama, Japan
Izumisano-shi, Osaka, Japan
Kashiwara-shi, Osaka, Japan
Osaka-shi, Osaka, Japan
Sakai-shi, Osaka, Japan
Suita-shi, Osaka, Japan
Toyonaka-shi, Osaka, Japan
Saga-shi, Saga, Japan
Fujimi-shi, Saitama, Japan
Saitama-shi, Saitama, Japan
Sayama-shi, Saitama, Japan
Tokorozawa-shi, Saitama, Japan
Fujinomiya-shi, Shizuoka, Japan
Shizuoka-shi, Shizuoka, Japan
Otsu-shi, Siga, Japan
Shimotsuga-gun, Tochigi, Japan
Shimotsuke-shi, Tochigi, Japan
Komatsu-shi, Tokushima, Japan
Bunkyo-ku, Tokyo, Japan
Chiyoda-ku, Tokyo, Japan
Chuo-ku, Tokyo, Japan
Hino-shi, Tokyo, Japan
Itabashi-ku, Tokyo, Japan
Katsushika-ku, Tokyo, Japan
Mitaka-shi, Tokyo, Japan
Nerima-ku, Tokyo, Japan
Ota-ku, Tokyo, Japan
Shinjuku-ku, Tokyo, Japan
Sibuya-ku, Tokyo, Japan
Toyoshima-ku, Tokyo, Japan
Sanyoonoda-shi, Yamaguchi, Japan
Shimonoseki-shi, Yamaguchi, Japan
Ube-shi, Yamaguchi, Japan
Sponsors and Collaborators

Responsible Party: Takeda Identifier: NCT01433406     History of Changes
Other Study ID Numbers: TAK-875/OCT-002
U1111-1124-1561 ( Registry Identifier: WHO )
JapicCTI-111602 ( Registry Identifier: JapicCTI )
First Posted: September 14, 2011    Key Record Dates
Last Update Posted: January 27, 2014
Last Verified: January 2014

Keywords provided by Takeda:
Drug Therapy

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases